Molecular Diagnostics held a 45.58% share of the point of care infectious disease testing market in 2025, reflecting its dominant position within the technology segment. This leadership is underpinned by its ability to deliver highly sensitive and specific results at the point of care, which is especially important when clinicians need dependable detection for infectious agents without the delays associated with centralized laboratory workflows. In the point of care infectious disease testing market, Molecular Diagnostics remains the preferred option where diagnostic confidence, faster clinical decisions, and improved infection management are critical to routine use.

Lateral Flow Immunoassay is the fastest-growing technology segment in the point of care infectious disease testing market because it aligns well with practical testing needs in decentralized settings. Its momentum is being aided by demand for rapid, simple, and easily deployable tests that can be used across clinics, emergency care environments, and resource-constrained locations without complex instrumentation. Compared with more technically intensive alternatives, Lateral Flow Immunoassay is seeing wider adoption through its operational convenience and broader usability, which makes it well suited for expanding access to point-of-care infectious disease screening.

Disease Segment Analysis: COVID-19 (Largest Segment) vs Pneumonia or Streptococcus Associated Infections (Fastest-Growing Segment)

Within the disease segment, COVID-19 accounted for a 64.99% share of the point of care infectious disease testing market in 2025, making it the dominant application area. Its continued leadership is rooted in the sustained need for rapid identification in frontline care settings, where timely diagnosis directly influences isolation decisions, treatment pathways, and patient flow management. The point of care infectious disease testing market has seen COVID-19 maintain its leading share because testing remains closely tied to immediate clinical action and infection control requirements across a wide range of healthcare environments.

Pneumonia or Streptococcus Associated Infections represent the fastest-growing disease segment in the point of care infectious disease testing market as care providers place greater emphasis on quick differentiation of respiratory and bacterial infections at the site of care. Growth is being influenced by the practical need to support earlier treatment decisions and reduce delays in identifying conditions that can worsen rapidly if not addressed promptly. Relative to more established testing categories, this segment is gaining momentum because point-of-care formats are increasingly valuable where immediate diagnostic direction can improve case management and support more targeted clinical intervention.